Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 173 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: UV Light Therapy Clear all
Completed Not applicable Interventional

Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients

NCT02088580
View directory record Official record
Conditions
Non-Psychotic Unipolar Depression, Bipolar Depression
Interventions
Triple Chronotherapy
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Early Feasibility Study of UV-Femtosecond Laser Assisted Lenticular Extraction

NCT03021707
View directory record Official record
Conditions
Refractive Error - Myopia Severe, Refractive Error - Myopia Simple
Interventions
WaveLight® Ultraviolet Femtosecond (FS) Laser System, Laser Assisted Lenticular Extraction
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Sioux Falls, South Dakota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 3, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gamma Frequency Stimulation in Individuals With Down Syndrome

NCT05196984
View directory record Official record
Conditions
Down Syndrome
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

NCT02296346
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
SoluMedrol, Extracorporeal Photopheresis
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 3, 2026, 5:15 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers

NCT05255016
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Efficacy of a Novel Prototype Gastrostomy Tube Anchor Dressing

NCT07115134
View directory record Official record
Conditions
Gastroenterology Surgery, Tube Feeding
Interventions
Bearables Gastrostomy Tube Dressing
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Not listed Phase 2Phase 3 Interventional

Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs

NCT01081561
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Yaron S. Rabinowitz M.D.
Other
Eligibility
21 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)

NCT01579370
View directory record Official record
Conditions
Multidrug Resistant Organisms, Healthcare Associated Infections
Interventions
Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light, Bleach and UV-C light
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 3, 2026, 5:15 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

NCT05027295
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
riboflavin ophthalmic solution
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

NCT01628029
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
Interventions
Counseling, Methylphenidate Hydrochloride, Phototherapy, Placebo Administration, Quality-of-Life Assessment, Sham Intervention, Therapeutic Melatonin
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Visible Light Study

NCT02663921
View directory record Official record
Conditions
Skin Disease, Pigment Disorders
Interventions
Part A: Baseline-Week 2, Part B: Week 4-Week 12
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

NCT04531527
View directory record Official record
Conditions
Dermatitis, Phototoxic
Interventions
Butenafine HCl 1% (BAY1896425)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2

NCT03192722
View directory record Official record
Conditions
Ocular Conditions Resulting in Visual Impairment
Interventions
Colored near reading glasses, Lighting as determined by LuxIQ/2 or OttLite Cobra
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT06663722
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, cGVHD
Interventions
Axatilimab, Extracorporeal Photopheresis
Biological · Procedure
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Not applicable Interventional

Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma

NCT06626334
View directory record Official record
Conditions
Rib Fractures, Pain, Acute
Interventions
Bright Blue Light, Bright Full-Spectrum (White) Light, Usual Ambient Light
Device
Lead sponsor
Rebecca E Kotcher, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

NCT03126539
View directory record Official record
Conditions
Aging
Interventions
Sulforaphane, Narrow-band Ultraviolet B exposure, 4 mm skin punch biopsy
Drug · Radiation · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Role of Sleep Reactivity in Shift Work Disorder

NCT05424406
View directory record Official record
Conditions
Shift-work Disorder
Interventions
Active phototherapy, Control phototherapy, Cognitive Behavioral Therapy (CBT), Sleep education control
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 3, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Effect of SOLIUS UV Light Source in Improving Vitamin D Status

NCT04780776
View directory record Official record
Conditions
Vitamin D Deficiency, Vitamin D Insufficiency
Interventions
UVB treatment, Sham comparator
Device
Lead sponsor
Boston University
Other
Eligibility
22 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 3, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 3, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Peripheral Blood Flow Responses to Electromagnetic Energy

NCT02370199
View directory record Official record
Conditions
Exposure to Man-made Visible Light
Interventions
670 nm light, octafluropropane
Device · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 5:15 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Progressive Keratoconus or Ectasia Treatment Plan

NCT01384773
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin Solution, UV-X Illumination System
Other · Device
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 3, 2026, 5:15 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 3, 2026, 5:15 AM EDT